13 results about "Squamous Cell Cancers" patented technology

The application discloses a photosensitizer conjugate for targeted treatment of tongue squamous cell carcinoma and a preparation method and application thereof, and belongs to the technical field of biological medicines. A novel PROTAC-PDT conjugate Gef-PRO-SS-TPE is synthesized, and the compound connects a PROTAC molecule Gef-PRO targeting EGFR and an AIE photosensitizer TPE derivative through a breakable disulfide bond. On one hand, Gef-PRO can specifically degrade EGFR and block tumor cell proliferation signals; on the other hand, the TPE derivative can generate ROS under light conditions and induce cell apoptosis. More importantly, the disulfide bond can be broken in response to high concentrations of glutathione (GSH) in tumor cells, realizing controllable release of Gef-PRO and TPE molecules, so as to exert a synergistic anti-tumor effect.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

This invention discloses a method and system for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma, belonging to the field of two-dimensional image processing technology for oral squamous cell carcinoma. It aims to improve the accuracy and stability of early screening for oral squamous cell carcinoma. The invention acquires oral image data, labels the acquired images according to pre-set classification standards to obtain training and testing sets; preprocesses the oral image data to obtain preprocessed training and testing sets; performs data augmentation on the oral image data in the training set to obtain a data-augmented training set; constructs an image feature extraction model based on a convolutional neural network; and trains the convolutional neural network-based image feature extraction model using supervised learning to obtain a trained convolutional neural network-based image feature extraction model for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma.

The application relates to application of FLVCR2-AS1 as a biomarker and therapeutic target of oral squamous cell carcinoma, and belongs to the technical field of biological medicine. The application provides application of FLVCR2-AS1 as a biomarker in preparation of a product for diagnosing oral squamous cell carcinoma, wherein the nucleotide sequence of the FLVCR2-AS1 is shown in SEQ ID NO:1. It is found and identified in the application that FLVCR2-AS1 is specifically lowly expressed in oral squamous cell carcinoma tissues and cell lines, and the expression level is significantly related to the prognosis of patients. Further research finds that overexpression of FLVCR2-AS1 can effectively inhibit the migration and invasion ability of oral squamous cell carcinoma cells. These results prove that FLVCR2-AS1 is a novel molecular target with clinical application potential for oral squamous cell carcinoma.

This invention provides the use of CX6258 or its salts in medicaments for the prevention and / or treatment of lung cancer, belonging to the field of biomedicine. This invention is the first to discover that CX6258HCl can effectively inhibit the growth of lung squamous cell carcinoma cell lines and organoids, and that CX6258HCl can also be combined with cisplatin to treat lung squamous cell carcinoma. Therefore, CX6258 or its salts have broad application prospects in medicaments for the prevention and / or treatment of lung cancer, especially lung squamous cell carcinoma.

The present application relates to the application of sheep oil in the preparation of anti-esophageal cancer cell function supplements, and the sheep oil is used as a nutritional supplement to reduce the esophageal cancer cell activity, maintain the body weight of the esophageal cancer patient, stabilize the nutrition and metabolism index, reduce the inhibition of radiotherapy on the hematopoietic system, improve the immune function of the esophageal cancer patient, reduce the inflammation reaction related to radiotherapy and protect the life quality of the esophageal cancer patient.The present application first proves the positive role of the sheep oil as a nutritional supplement in the treatment of esophageal squamous cell carcinoma patients, especially for the locally advanced unresectable esophageal squamous cell carcinoma patients, and provides a function supplement with lower cost and better effect for the future treatment of esophageal squamous cell carcinoma patients, which has important significance.

This invention relates to a methylation site marker for assisting in the early diagnosis of esophageal squamous cell carcinoma and its application, belonging to the field of biomedical technology. The methylation site marker is one or a combination of methylation sites cg05064044, cg03395511, and cg21548813 in human peripheral blood mononuclear cells, with nucleotide sequences shown in SEQ ID NO. 1-3. This invention uses methylation chip detection to find that the methylation levels of cg05064044, cg03395511, and cg21548813 in peripheral blood mononuclear cells of esophageal squamous cell carcinoma patients were significantly higher than those in healthy controls. Further analysis revealed that the methylation levels of cg05064044, cg03395511, and cg21548813 in PBMCs of esophageal squamous cell carcinoma patients in both the training and validation cohorts were significantly higher than those in healthy controls. Finally, ROC curve analysis confirmed that the three methylation sites cg05064044, cg03395511, and cg21548813 have good specificity and sensitivity, and have high diagnostic efficacy when used alone or in combination for the diagnosis of esophageal squamous cell carcinoma. They can be used as potential molecular markers for the diagnosis of esophageal squamous cell carcinoma.

The application discloses a method for monitoring esophageal squamous cell carcinoma treatment effect based on multi-omics dynamic ctDNA, comprising the following steps: S1, analyzing ctDNA targeted sequencing data and cfMeDIP-seq data; S2, identifying WGBS differential methylation regions; S3, identifying TCGA450K methylation chip differential methylation probes; S4, identifying cfMeDIP-seq differential methylation regions; S5, methylation risk scoring; S6, defining a methylation immune index as an evaluation index for evaluating the prognosis of neoadjuvant immunotherapy; and S7, constructing a multi-omics mixed model by using a Logistic Regression method, so that a model risk score is obtained. The application integrates dynamic characteristics of genomics and epigenetics at multiple time points, constructs a machine learning model, predicts the response of esophageal squamous cell carcinoma neoadjuvant immunotherapy, and evaluates the primer, probe combination and classification model of esophageal cancer prognosis.

In some embodiments, the present disclosure provides methods of treating a cancer in a subject in need thereof, wherein the cancer is selected from pancreatic cancer, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell cancer (HNSCC) comprising administering to the subject a bispecific antibody comprising a first antigen-binding region that binds a Vγ9Vδ2 T cell receptor (TCR) a second antigen-binding region that binds to EFGR. In some embodiments, the pancreatic cancer is pancreatic ductal adenocarcinoma.

The objective is to provide a composition that can suppress diseases other than oral diseases. [Solution] The present invention is a growth inhibitor for Fusobacterium bacteria containing cyclodextran and / or its derivatives. Due to its inhibitory effect on Fusobacterium bacteria, it contributes to the treatment and prevention of ulcerative colitis, liver cirrhosis, obesity, colorectal cancer, esophageal cancer, oral cancer, breast cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, premature birth, and endometriosis ulcers.

Provided herein are methods and compositions for reducing the expression and / or activity of an oncogenic transfer RNA (tRNA). Composition for treating cancer in the subject are disclosed, comprising an inhibitor of an oncogenic transfer RNA (tRNA) to a subject in need thereof, wherein the oncogenic tRNA comprises an inhibitory nucleic acid such as ARG-TCT-4-1, an siRNA, an shRNA, an miRNA, an antisense oligonucleotide, or a nucleic acid modification such as a locked nucleic acid, a phosphorothioate modification, a 2′—O-methyl modification, a 2′—O-methoxyethyl modification, a 2′-fluoro modification, a phosphorodiamidate modification, or a mesylphosphoramidate modification. The disclosed compositions are disclosed as treating cancers such as a sarcoma, a glioblastoma, an adrenocortical carcinoma, a cholangiocarcinonma, a melanoma, a glioma, a diffuse glioma, a mature B cell neoplasm, a non-small cell lung cancer, an esophagogastric adenocarcinoma, a pheochromocytoma, a hepatocellular carcinoma, an endometrial carcinoma, a pancreatic adenocarcinoma, a breast carcinoma, an invasive breast carcinoma, a head and neck squamous cell carcinoma, a bladder urothelial carcinoma, a colorectal adenocarcinoma, an ovarian epithelial tumor, a prostate adenocarcinoma, a cervical squamous cell carcinoma, a renal non-clear cell carcinoma, or a renal clear cell carcinoma.

This invention discloses a strain of *Veillonella parvula* and its application in the preparation of products for the diagnosis and treatment of oral squamous cell carcinoma (OSCC), belonging to the field of microbial applications. This invention discloses a strain of *Veillonella parvula*, with the accession number CGMCC No. 25592. Using high-throughput 16S rDNA sequencing and bioinformatics analysis of saliva 16S rRNA sequencing data from 11 OSCC patients and a control group, this invention identified *Veillonella parvula*, which was significantly reduced in the saliva of OSCC patients. Experimental verification showed that the metabolites of *Veillonella parvula* can effectively inhibit the proliferation and invasion of TROP2-overexpressing oral squamous cell carcinoma cells and significantly promote their apoptosis. Therefore, this invention provides a new direction for the diagnosis and treatment of TROP2-overexpressing oral squamous cell carcinoma.

This invention relates to the pharmaceutical field, specifically to a combination drug of trifluoperazine and a PD-1 inhibitor and its uses. This invention, through the combined use of trifluoperazine and a PD-1 inhibitor in the treatment of oral squamous cell carcinoma, has achieved superior efficacy compared to monotherapy. The combination of trifluoperazine and a PD-1 inhibitor in this invention increases CD8... + T cell expression levels and CD3 + CD8 + CD25 + Regarding the proportion of T cell subsets, it has a synergistic effect, providing a new strategy for the treatment of oral squamous cell carcinoma and showing great application prospects.